The Biden administration’s decision to stop opposing a proposed COVID-19 waiver of certain intellectual-property rights under World Trade Organization rules is a welcome move. But ending the pandemic also requires scaling up knowledge and technology transfer, as well as public production of vaccine supplies.
The reasons why people may not take a COVID-19 vaccine even when offered can be complex and varied, but they point to the need to tackle them better if we are to improve vaccine coverage.
The pandemic has been tough for the 1.4 million Ugandans living with HIV, but the arrival of the COVID-19 vaccine has brought some welcome relief.
Increasing vaccination coverage by even 1% can save thousands of lives and millions of dollars in medical and economic costs.
The rollout of the first phase of the COVID-19 vaccination exercise has not been without its challenges but there is a focus on learning and improving.
As countries worldwide are suffering from COVID-19 vaccine shortages, sharing intellectual property and know-how, and easing trade bans on the export of raw materials, could ease supply bottlenecks.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
We cannot look back in the future and know we could have done more.
Even before SARS-CoV-2 swept around the world, scientists had been warning of the global threat posed by viruses like it. Although COVID-19 vaccines should help to end the current coronavirus pandemic, it is unlikely to be the last.
With 47 African countries now rolling out COVID-19 vaccines and over 17 million doses given on the continent, early insights from Africa’s largest-ever immunization drive offer hope, inspiration and early, yet vital lessons. Here, we shine a light on key lessons emerging from countries that have made strong progress, including Angola, Ghana, Mauritius and Rwanda.